Product Description
SALSA® MLPA® Probemix P383-A2 T-ALL

To be used with the MLPA General Protocol.

Version A2
As compared to version A1, several probes have small changes in the length but no change in the sequences detected. For complete product history see page 122.

Catalogue numbers:
- **P383-025R:** SALSA MLPA Probemix P383 T-ALL, 25 reactions.
- **P383-050R:** SALSA MLPA Probemix P383 T-ALL, 50 reactions.
- **P383-100R:** SALSA MLPA Probemix P383 T-ALL, 100 reactions.

To be used in combination with a SALSA MLPA reagent kit and Coffalyser.Net data analysis software. MLPA reagent kits are either provided with FAM or Cy5.0 dye-labelled PCR primer, suitable for Applied Biosystems and Beckman/SCIEX capillary sequencers, respectively (see www.mrcholland.com).

Certificate of Analysis
Information regarding storage conditions, quality tests, and a sample electropherogram from the current sales lot is available at www.mrcholland.com.

Precautions and warnings
For professional use only. Always consult the most recent product description AND the MLPA General Protocol before use: www.mrcholland.com. It is the responsibility of the user to be aware of the latest scientific knowledge of the application before drawing any conclusions from findings generated with this product.

General information
The SALSA MLPA Probemix P383 T-ALL is a **research use only (RUO)** assay for the detection of deletions or duplications in 13 different chromosomal regions, which are suggested to be of diagnostic and/or prognostic importance in T-ALL.

T-lineage acute lymphoblastic leukemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of adult ALL cases (Iacobucci and Mullighan 2017). Although prognosis has improved due to effective treatment protocols, around 25% of paediatric and 50-70% of adult patients still experience relapse. T-ALL is genetically heterogeneous, and comprises multiple distinct subtypes defined by chromosomal rearrangements that usually involve one of the T-cell receptor (TCR) loci, but non-TCR-driven translocations are also detected. In addition, genome-wide characterisation has identified several novel amplifications, deletions and point mutations in T-ALL samples that are of interest to better define T-ALL subgroups (Girardi et al. 2017).

This SALSA MLPA probemix is not CE/FDA registered for use in diagnostic procedures. Purchase of this product includes a limited license for research purposes.

Gene structure and transcript variants:
Entrez Gene shows transcript variants of each gene: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene
Matched Annotation from NCBI and EMBL-EBI (MANE): https://www.ncbi.nlm.nih.gov/refseq/MANE/ and http://tark.ensembl.org/
For NM_ mRNA reference sequences: http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide
Locus Reference Genomic (LRG) database: http://www.lrg-sequence.org/

Exon numbering
The LRG or RefSeq transcript NM sequences used for exon numbering in this P383-A2 T-ALL product description are provided in Table 2 below. The exon numbering of the NM_ sequence that was used for determining a probe's ligation site does not always correspond to the exon numbering obtained from the LRG

sequences. As changes to the databases can occur after release of this product description, the NM_ sequence and exon numbering may not be up-to-date.

Probemix content
The SALSA MLPA Probemix P383-A2 T-ALL contains 56 MLPA probes with amplification products between 130 and 504 nucleotides (nt). This includes probe(s) for 13 chromosomal regions, including *STIL-TAL1* (1p33), *LEF1* (4q25), *CASP8AP2* (6q15), *MYB* (6q23), *EZH2* (7q36) *MLLT3+MTAP+CDKN2A/B* (9p21), *NUP214-ABL1* (9q34), *PTEN* (10q23), *LMO1* (11p15), *LMO2* (11p13), *NF1+SUZ12* (17q11), *PTPN2* (18p11) and *PHF6* (Xq26). In this probemix, 40 out of the 56 MLPA probes are used as reference probes, as they are spread over a number of different chromosomal regions and it is expected that the majority of these probes will have a normal copy number in most samples. Complete probe sequences are available in Table 2 and online (www.mrcholland.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment (see table below). More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mrcholland.com.

Length (nt)	Name
64-70-76-82	Q-fragments (only visible with <100 ng sample DNA)
88-96	D-fragments (low signal indicates incomplete denaturation)
92	Benchmark fragment
100	X-fragment (X chromosome specific)
105	Y-fragment (Y chromosome specific)

MLPA technique
The principles of the MLPA technique (Schouten et al. 2002) are described in the MLPA General Protocol (www.mrcholland.com). More information on the use of MLPA in tumour applications can be found in Hömig-Hölzel and Savola (2012).

MLPA technique validation
Internal validation of the MLPA technique using 16 DNA samples from healthy individuals of the same sex is required, in particular when using MLPA for the first time, or when changing the sample handling procedure, DNA extraction method or instruments used. This validation experiment should result in a standard deviation ≤0.10 for all reference probes over the experiment.

Required specimens
Extracted DNA, free from impurities known to affect MLPA reactions. For more information please refer to the section on DNA sample treatment found in the MLPA General Protocol.

Reference samples
A sufficient number (≥3) of reference samples should be included in each MLPA experiment for data normalisation. All samples tested, including reference DNA samples, should be derived from the same tissue type, handled using the same procedure, and prepared using the same DNA extraction method when possible. Reference samples should be derived from different healthy individuals without a history of acute lymphoblastic leukemia. It is recommended to use samples of the same sex to facilitate interpretation. More information regarding the selection and use of reference samples can be found in the MLPA General Protocol (www.mrcholland.com).

Positive control DNA samples
MRC Holland cannot provide positive DNA samples. Inclusion of a positive sample in each experiment is recommended. Coriell Institute (https://catalog.coriell.org) and Leibniz Institute DSMZ (https://www.dsmz.de/) have diverse collections of biological resources which may be used as positive

control DNA samples in your MLPA experiments. The samples in the table below have been tested with this P383-A2 probemix at MRC Holland and can be used as a positive control sample(s) to detect duplications and deletions in different chromosomal regions. The quality of cell lines can change; therefore samples should be validated before use.

Sample name	Source	Chromosomal position (hg18) of copy number alteration*	Altered target genes in P383-A2	Expected copy number alteration
NA00501	Coriell Institute	4q25	*LEF1*	Heterozygous duplication
NA00782	Coriell Institute	4q25	*LEF1*	Heterozygous duplication
NA01221	Coriell Institute	6q15	*CASP8AP2*	Heterozygous duplication
NA07994	Coriell Institute	6q23.3	*MYB* and *AHI1*	Heterozygous duplication
NA09367	Coriell Institute	6q23.3	*MYB* and *AHI1*	Heterozygous duplication
NA01220	Coriell Institute	7q36.1	*EZH2*	Heterozygous duplication
NA12519	Coriell Institute	7q36.1	*EZH2*	Homozygous duplication
NA07412	Coriell Institute	7q36.1	*EZH2*	Heterozygous deletion
NA02819	Coriell Institute	9p21.3	*MLLT3, MTAP* and *CDKN2A/2B*	Heterozygous duplication
NA03226	Coriell Institute	9p21.3	*MLLT3, MTAP* and *CDKN2A/2B*	Heterozygous duplication
NA05067	Coriell Institute	9p21.3	*MLLT3, MTAP* and *CDKN2A/2B*	Heterozygous duplication
NA13685	Coriell Institute	9q34.12-q34.13	*ABL1, NUP214*	Heterozygous duplication
NA20125	Coriell Institute	10q23.31	*PTEN*	Heterozygous duplication
NA09709	Coriell Institute	11p13-p12	*LMO2, CD44, SLC1A2, RAG2*	Heterozygous deletion
NA01359	Coriell Institute	18p11.21	*PTPN2*	Heterozygous duplication
NA06870	Coriell Institute	18p11.21	*PTPN2*	Homozygous duplication
NA50136	Coriell Institute	18p11.21	*PTPN2*	Heterozygous deletion
NA03623	Coriell Institute	18p11.21	*PTPN2*	Heterozygous duplication
		Xq25-q26.3	*SH2D1A, PHF6, ARHGEF6*	Heterozygous duplication
NA01416	Coriell Institute	Xq25-q26.3	*SH2D1A, PHF6, ARHGEF6*	Homozygous duplication
NA20027	Coriell Institute	Xq25-q26.3	*SH2D1A, PHF6, ARHGEF6*	Heterozygous deletion

* Indicated chromosomal bands accommodate genes targeted by MLPA probes, however, the whole extent of copy number alteration (CNA) present in this cell line cannot be determined by this P383-A2 T-ALL probemix.

Data analysis
Coffalyser.Net software should be used for data analysis in combination with the appropriate lot-specific MLPA Coffalyser sheet. For both, the latest version should be used. Coffalyser.Net software is freely downloadable at www.mrcholland.com. Use of other non-proprietary software may lead to inconclusive or false results. For more details on MLPA quality control and data analysis, including normalisation, see the Coffalyser.Net Reference Manual.

Interpretation of results
The standard deviation of each individual reference probe over all the reference samples should be ≤0.10. When this criterion is fulfilled, the following cut-off values for the FR of the probes can be used to interpret MLPA results when **reference samples of the same sex** have been used:

Copy number status		Final ratio (FR)
Autosomal sequences and X chromosome sequences in females	**X chromosome sequences in males**	
Normal	Normal	0.80 < FR < 1.20
Homozygous deletion	Deletion	FR = 0
Heterozygous deletion		0.40 < FR < 0.65
Heterozygous duplication		1.30 < FR < 1.65
Heterozygous triplication/homozygous duplication	Duplication	1.75 < FR < 2.15
Ambiguous copy number		All other values

Note: The term "dosage quotient", used in older product description versions, has been replaced by "final ratio" to become consistent with the terminology of the Coffalyser.Net software. (Calculations, cut-offs and interpretation remain unchanged.) Please note that the Coffalyser.Net software also shows arbitrary borders as part of the statistical analysis of results obtained in an experiment. As such, arbitrary borders are different from the final ratio cut-off values shown here above.

Please note that these above mentioned final ratios are only valid for germline testing. Final ratios are affected both by percentage of tumour cells and by possible subclonality.

- Arranging probes according to chromosomal location facilitates interpretation of the results and may reveal more subtle changes such as those observed in subconal cases.
- False positive results: Please note that abnormalities detected by a single probe (or multiple consecutive probes) still have a considerable chance of being a false positive result. Sequence changes (e.g. SNVs, point mutations) in the target sequence detected by a probe can be one cause. Incomplete DNA denaturation (e.g. due to salt contamination) can also lead to a decreased probe signal, in particular for probes located in or near a GC-rich region. The use of an additional purification step or an alternative DNA extraction method may resolve such cases. Additionally, contamination of DNA samples with cDNA or PCR amplicons of individual exons can lead to an increased probe signal (Varga et al. 2012). Analysis of an independently collected secondary DNA sample can exclude these kinds of contamination artefacts.
- Normal copy number variation in healthy individuals is described in the database of genomic variants: http://dgv.tcag.ca/dgv/app/home. Users should always consult the latest update of the database and scientific literature when interpreting their findings.
- Not all abnormalities detected by MLPA are pathogenic. In some genes, intragenic deletions are known that result in very mild or no disease (as described for *DMD* by Schwartz et al. 2007). For many genes, more than one transcript variant exists. Copy number changes of exons that are not present in all transcript variants may not have clinical significance. Duplications that include the first or last exon of a gene (e.g. exons 1-3) might not result in inactivation of that gene copy.
- False results can be obtained if one or more peaks are off-scale. For example, a duplication of one or more exons can be obscured when peaks are off-scale, resulting in a false negative result. The risk on off-scale peaks is higher when probemixes are used that contain a relatively low number of probes. Coffalyser.Net software warns for off-scale peaks while other software does not. If one or more peaks are off-scale, rerun the PCR products using either: a lower injection voltage or a shorter injection time, or a reduced amount of sample by diluting PCR products.

P383 specific notes

- We recommend treating each probe as a reference probe with the exception of the chromosome 9 and Xq probes.
- In samples from tumour tissues, reference probes are more prone to have deviating copy number results as compared to blood derived germline samples. When regions targeted by reference probes are affected by copy number alterations, it can help to turn the slope correction off in Coffalyser.Net analysis to get the correct copy number interpretation on the target region.

Limitations of the procedure

- In most populations, the major cause of genetic defects in the genes included in this probemix are small (point) mutations, most of which will not be detected by using SALSA MLPA Probemix P383 T-ALL.
- MLPA cannot detect any changes that lie outside the target sequence of the probes and will not detect copy number neutral inversions or translocations. Even when MLPA did not detect any aberrations, the possibility remains that biological changes in that gene or chromosomal region *do* exist but remain undetected.
- Sequence changes (e.g. SNVs, point mutations) in the target sequence detected by a probe can cause false positive results. Mutations/SNVs (even when >20 nt from the probe ligation site) can reduce the probe signal by preventing ligation of the probe oligonucleotides or by destabilising the binding of a probe oligonucleotide to the sample DNA.
- MLPA analysis on tumour samples provides information on the *average* situation in the cells from which the DNA sample was purified. Gains or losses of genomic regions or genes may not be detected if the percentage of tumour cells is low. In addition, subclonality of the aberration affects the final ratio of the corresponding probe. Furthermore, there is always a possibility that one or more reference probes *do* show a copy number alteration in a patient sample, especially in tumours with more chaotic karyotypes.

Confirmation of results

Copy number changes detected by only a single probe always require confirmation by another method. An apparent deletion detected by a single probe can be due to e.g. a mutation/polymorphism that prevents ligation or destabilises the binding of probe oligonucleotides to the DNA sample. Sequence analysis can establish whether mutations or polymorphisms are present in the probe target sequence. The finding of a heterozygous mutation or polymorphism indicates that two different alleles of the sequence are present in the sample DNA and that a false positive MLPA result was obtained.

Copy number changes detected by more than one consecutive probe should be confirmed by another independent technique such as long range PCR, qPCR, array CGH or Southern blotting, whenever possible. Deletions/duplications of more than 50 kb in length can often be confirmed by FISH.

COSMIC mutation database

http://cancer.sanger.ac.uk/cosmic. We strongly encourage users to deposit positive results in the COSMIC Database. Recommendations for the nomenclature to describe deletions/duplications of one or more exons can be found on http://varnomen.hgvs.org/.

Please report, false positive results due to SNVs and unusual results (e.g., a duplication of *LEF1* exons 1 and 7 but not exon 4) to MRC Holland: info@mrcholland.com.

Table 1. SALSA MLPA Probemix P383-A2 T-ALL

Length (nt)	SALSA MLPA probe	Chromosomal position (hg18)[a]		Used as reference probe	Location (hg18) in kb
		Chromosomal band	Exon		
64-105	Control fragments – see table in probemix content section for more information				
130	**STIL** probe 15947-L18099	1p33	Exon 1	Ref	01-047,552
137 ¥	**PHF6** probe 18550-L29679	Xq26.2	Exon 1	-	X-133,335
142	**TAL1** probe 13063-L23841	1p33	Exon 3	Ref	01-047,468
147 «	**MYB** probe 12500-L18025	6q23.3	Exon 2	Ref	06-135,549
152	**RAG2** probe 18551-L23889	11p12	Exon 2	Ref	11-036,572
157	**MLLT3** probe 12533-L23842	9p21.3	Exon 1	-	09-020,612
161	**PHF6** probe 15948-L23843	Xq26.2	Exon 3	-	X-133,340
166	**CASP8AP2** probe 15949-L23844	6q15	Exon 1	Ref	06-090,596
170	**MLLT3** probe 16058-L23880	9p21.3	Exon 7	-	09-020,353
176 Ж ±	**PTPN2** probe 15951-SP0316-L23881	18p11.21	Exon 1	Ref	18-012,874
182	**CDKN2A** probe 11869-L19013	9p21.3	Exon 1	-	09-021,965
190 ¬	SH2D1A probe 06104-L05559	Xq25	-	-	X-123,308
196	**LMO2** probe 12538-L23846	11p13	Exon 6	Ref	11-033,837
202 ¬	ARHGEF6 probe 02902-L02296	Xq26.3	-	-	X-135,585
208 Ж	**PTPN2** probe 18549-SP0318-L23866	18p11.21	Exon 4	Ref	18-012,821
214	**PTEN** probe 13691-L23847	10q23.31	Exon 7	Ref	10-089,708
220	**LEF1** probe 12507-L24045	4q25	Exon 1	Ref	04-109,309
226	**PHF6** probe 15954-L23884	Xq26.2	Exon 7	-	X-133,376
233	**PTEN** probe 13685-L17760	10q23.31	Exon 1	Ref	10-089,614
239 Ж	**PTPN2** probe 15955-SP0317-L18107	18p11.21	Exon 2	Ref	18-012,849
244 Ж	**LMO1** probe 16714-SP0381-L23885	11p15.4	Exon 2	Ref	11-008,209
250	**NF1** probe 03849-L18072	17q11.2	Exon 26	Ref	17-026,584
257	**CDKN2B** probe 17935-L23887	9p21.3	Exon 2	-	09-021,996
263	**EZH2** probe 18269-L23383	7q36.1	Exon 3	Ref	07-148,175
269	**CASP8AP2** probe 15957-L18109	6q15	Exon 2	Ref	06-090,613
274	**STIL** probe 15112-L16883	1p33	Exon 6	Ref	01-047,538
281 ¥	**CDKN2A** probe 16533-L29647	9p21.3	Exon 3	-	09-021,958
287	**ABL1** probe 18552-L24043	9q34.12	Exon 4	-	09-132,720
292	**MYB** probe 17265-L20654	6q23.3	Exon 16	Ref	06-135,581
299 ¬	AHI1 probe 15960-L18112	6q23.3	-	Ref	06-135,648
304	**EZH2** probe 18272-L23021	7q36.1	Exon 14	Ref	07-148,143
311	**SUZ12** probe 18705-L23805	17q11.2	Exon 15	Ref	17-027,348
319 ¥	**ABL1** probe 12516-L29680	9q34.12	Exon 12	-	09-132,749
326 «	**MYB** probe 00441-L24480	6q23.3	Exon 6	Ref	06-135,555
334	**MTAP** probe 15678-L22421	9p21.3	Exon 1	-	09-021,793
343 Ж	**LMO1** probe 16717-SP0380-L19731	11p15.4	Exon 4	Ref	11-008,203
351	**RAG2** probe 16520-L23853	11p12	Exon 1	Ref	11-036,576
361	**NUP214** probe 18553-L23891	9q34.13	Exon 2	-	09-132,993
371 ¥	**TAL1** probe 12520-L29681	1p33	Exon 6	Ref	01-047,458
377	**LEF1** probe 15964-L23859	4q25	Exon 6	Ref	04-109,222
382	**LMO2** probe 12558-L23858	11p13	Exon 1	Ref	11-033,870
391	**PHF6** probe 15965-L24481	Xq26.2	Exon 11	-	X-133,388
400	**NF1** probe 02530-L23856	17q11.2	Exon 58	Ref	17-026,725
409	**CASP8AP2** probe 15967-L23854	6q15	Exon 6	Ref	06-090,624
417	**LEF1** probe 15968-L18120	4q25	Exon 3	Ref	04-109,304
426	**CD44** probe 00669-L23838	11p13	Exon 19	Ref	11-035,207
433	**CASP8AP2** probe 15969-L24482	6q15	Exon 11	Ref	06-090,640
439	**PTEN** probe 13692-L23864	10q23.31	Exon 7	Ref	10-089,708
445	**STIL** probe 15125-L23865	1p33	Exon 12	Ref	01-047,519

Length (nt)	SALSA MLPA probe	Chromosomal position (hg18)[a]		Used as reference probe	Location (hg18) in kb
		Chromosomal band	Exon		
454	**LEF1** probe 12526-L29682	4q25	Exon 12	Ref	04-109,189
462	**PTPN2** probe 15970-L23850	18p11.21	Exon 9	Ref	18-012,784
469 Ж	**EZH2** probe 18555-SP0635-L23020	7q36.1	Exon 20	Ref	07-148,135
475	**PTEN** probe 13696-L17520	10q23.31	Exon 9	Ref	10-089,715
481 ¥	**SLC1A2** probe 18698-L29605	11p13	Exon 13	Ref	11-035,244
492	**NUP214** probe 18547-L24044	9q34.13	Exon 23	-	09-133,041
504	**SUZ12** probe 18539-L23848	17q11.2	Exon 10	Ref	17-027,340

[a] See section Exon numbering on page 1 for more information.

¥ Changed in version A2. Minor alteration, no change in sequence detected.

± SNP rs200164592 could influence the probe signal. In case of apparent deletions, it is recommended to sequence the region targeted by this probe.

« Probe located in or near a GC-rich region. A low signal can be caused by salt contamination in the DNA sample leading to incomplete DNA denaturation, especially of GC-rich regions.

Ж This probe consists of three parts and has two ligation sites. A low signal of this probe can be due to depurination of the sample DNA, e.g. due to insufficient buffering capacity or a prolonged denaturation time. When this occurs in reference samples, it can look like an increased signal in the test samples.

¬ Flanking probe. Included to help determine the extent of a deletion/duplication. Copy number alterations of only the flanking or reference probes are unlikely to be related to the condition tested.

SNVs located in the target sequence of a probe can influence probe hybridization and/or probe ligation. Please note: not all known SNVs are mentioned in the tables above. Single probe aberration(s) must be confirmed by another method.

Table 2. P383-A2 probes arranged according to chromosomal location

Length (nt)	SALSA MLPA probe	Gene/Exon[a]	Location (hg18)/ Ligation site	**Partial sequence**[b] (24 nt adjacent to ligation site)	Distance to next probe
***STIL-TAL1* fusion**, at 1p33 Sub-microscopic interstitial deletions (~90 kb, most commonly starting at chr1:047,470,111 and ending at chr1:047,552,032; hg18) encompassing the 5' UTR region of the *TAL1* gene and the last *STIL* exons, lead to a *STIL-TAL1* fusion gene leading to increased expression of *TAL1* (Brown et al. 1990). A *STIL-TAL1* fusion is found in 10-30% of T-ALL cases with a normal karyotype and is suggested to be associated with a favourable outcome (Cave et al. 2004). ^ Decreased signal of the probes for STIL exons 6 and 12 is indicative for the formation of a *STIL-TAL1* fusion gene.					
371	12520-L29681	***TAL1***, ex 6	NM_003189.5; 1052-1053	GCAGCAGAATGT-GAACGGGGCCTT	9.4 kb
142	13063-L23841	***TAL1***, ex 3	NM_003189.5; 120 nt before ex 3	CCCTGGACTGGT-TGGTCGGGGACA	51.5 kb
445 ^	15125-L23865	***STIL***, ex 12	NM_001048166.1; 1660-1661	TCTTTTGAGACA-CTGCAAAGTAAG	19.1 kb
274 ^	15112-L16883	***STIL***, ex 6	NM_001048166.1; 668-669	CTGCTTTCCCTA-AGAGTTCATATC	14.0 kb
130	15947-L18099	***STIL***, ex 1	NM_001048166.1; 26-27	CAACGTCCCAGA-GGCGGGGCCGGA	-
***LEF1* gene**, at 4q25 Mono/biallelic microdeletions of *LEF1* are detected in 11% of children with T-ALL, and its inactivation seems to correlate with better survival and with younger age at diagnosis. The first exons of *LEF1* are frequently deleted (Gutierrez et al. 2010).					
454	12526-L29682	***LEF1***, ex 12	NM_016269.5; 2539-2540	CTAGAGACGCTG-ATCCATAAAGAC	33.1 kb
377	15964-L23859	***LEF1***, ex 6	NM_016269.5; 1831-1832	TATCCCATCACG-GGTGGATTCAGG	82.0 kb
417	15968-L18120	***LEF1***, ex 3	NM_016269.5; 1533-1534	TATGAATAACGA-CCCATACATGTC	4.6 kb
220	12507-L24045	***LEF1***, ex 1	NM_016269.5; 697-698	GCATCCGGGGTA-ACTACAGTGGAG	-
***CASP8AP2* gene**, at 6q15 Deletion of 6p15-p16.1, including the *CASP8AP2* gene, is detected in 12% of T-ALL patients and is suggested to associate with poor early treatment response (Remke et al. 2009).					
166	15949-L23844	***CASP8AP2***, ex 1	NM_012115.4; 127-128	GTAGTCCCCCGA-GTGGAGGTCGGC	16.6 kb

269	15957-L18109	***CASP8AP2***, ex 2	NM_012115.4; 255-256	GGAAATAGGATC-ATGGCAGCAGAT	10.5 kb
409	15967-L23854	***CASP8AP2***, ex 6	NM_012115.4; 596-597	TCTTAAGAAGAA-TATTTCAGCACT	16.8 kb
433	15969-L24482	***CASP8AP2***, ex 11	NM_012115.4; 6367-6368	TTTCACATCAGC-ATGTTCAGCTTG	45 **M**b to *MYB* gene

***MYB* gene**, at 6q23.3
Duplication of the *MYB* oncogene is detected in 8-15% of the individuals with T-ALL (Clappier et al. 2007; O'Neil et al. 2007). In most cases, the 3' end of the *AHI1* gene is also duplicated together with *MYB*. The sub-microscopic size of the aberration makes this duplication undetectable by conventional cytogenetics/FISH in most cases (Lahortiga et al. 2007).

147 «	12500-L18025	***MYB***, ex 2	NM_001130173.2; 265-266	TGAGGACTTTGA-GATGTGTGACCA	6.4 kb
326 «	00441-L24480	***MYB***, ex 6	NM_001130173.2; 782-783	ATGCGTCGGAAG-GTCGAACAGGAA	26.1 kb
292	17265-L20654	***MYB***, ex 16	NM_001130173.2; 2969-2970	CATTTAATCCAG-ATTGTAAATGCT	66.9 kb
299 ¬	15960-L18112	*AHI1*	6q23.3	GAAAACACTGTA-ATTGCTACTCAG	-

***EZH2* gene**, at 7q36.1
The *EZH2* gene has been shown to be inactivated by loss-of-function mutations and deletions in up to 25% of T-ALL patients (Ntziachristos et al. 2012; Zhang et al. 2012). Moreover, loss of *EZH2* in hematopoietic stem cells has been shown to cause aggressive T-ALL in mice (Simon et al. 2012).
Exon numbering for *EZH2* is from the RefSeq transcript NM_004456, which is identical to the LRG_531 sequence.

469 Ж	18555-SP0635-L23020	***EZH2***, ex 20	NM_004456.5; 2605-2606 and 2649-2650	TTTTGCAATAAT-44nt spanning oligo-TTGTCCTTGTTG	7.6 kb
304	18272-L23021	***EZH2***, ex 14	NM_004456.5; 1761-1762	TGCCCTTGTGTG-ATAGCACAAAAT	31.6 kb
263	18269-L23383	***EZH2***, ex 3	NM_004456.5; 318-319	CAAGAATGGAAA-CAGCGAAGGATA	-

***CDKN2A/B*, *MLLT3* and *MTAP* genes,** at 9p21.3
CDKN2A/B inactivation is found in 50-60% of all T-ALL cases. In a considerable number of patient samples, this deletion is sub-microscopic and is not detectable by conventional cytogenetics or by FISH (Usvasalo et al. 2008; Sulong et al. 2009). Another suggested target gene in the chromosomal region is *MLLT3*, which is deleted in 26% of T-ALL patients (Mullighan et al. 2007). *CDKN2A/B* deletions are suggested to associate with poor outcome in both paediatric and adult T-ALL (Fizzotti et al. 1995; Yamada et al. 1997).
From product description version A2-04 onwards, the exon numbering from the MANE transcripts is used for *CDKN2A*. Consequently, for *CDKN2A*, the exon numbering has been changed: NM_000077.5 (MANE Select) encoding p16INK4A and NM_058195.4 (MANE Plus Clinical) encoding p14ARF are used. Both NM_000077.5 and NM_058195.4 have distinct first exons (both numbered as exon 1) which contain the translation start codon, and share a common second exon, which is translated in different reading frames (see schematic presentation below). The exon numbering (LRG_11 for *CDKN2A*), used in previous versions of this product description, can be found in between brackets. **Please be aware that the MANE and LRG exon numbering do not correspond for *CDKN2A*, and MANE exon numbering used here may differ from literature.**

170	16058-L23880	***MLLT3***, ex 7	NM_004529.4; 1524-1525	GATAACGACAAT-GACTCTGAAATG	258.9 kb
157	12533-L23842	***MLLT3***, ex 1	NM_004529.4; 124-125	TGTCCGCCATCT-ACCCTCCGCTCC	1.2 **M**b
334 #	15678-L22421	***MTAP***, ex 1	9p21.3	GCCCACTGCAGA-TTCCTTTCCCGT	165.5 kb
281	16533-L29647	***CDKN2A***, ex 3 (4)	NM_000077.5 & NM_058195.4; 33 nt before ex 3	TTGACCTCAGGT-TTCTAACGCCTG	7.0 kb
182	11869-L19013	***CDKN2A***, intron 1 (2)	NM_000077.5; 378 nt before ex 1; NM_058195.4; 4,0 kb before ex 2	CACGCCTTTGCT-GGCAGGCGGGGG	30.6 kb
257	17935-L23887	***CDKN2B***, ex 2	9p21.3	GCCTGTCTGAGA-CTCACAGGAAGG	110 **M**b to *ABL1* gene

***NUP214-ABL1* fusion gene**, at 9q34.12-q34.13
Amplification of the *NUP214-ABL1* fusion gene is observed in 6% of T-ALL and is suggested to be associated with an aggressive disease course (Graux et al. 2004; Graux et al. 2009). Detection of *NUP214-ABL1* fusion amplification is potentially both of prognostic and clinical significance, as patients with *NUP214-ABL1* fusion amplification could benefit from treatment with tyrosine kinase inhibitors.
Exon numbering for *ABL1* is according to LRG_769 (RefSeq transcript NM_007313).
Exon numbering for *NUP214* is according to LRG_1383.

287	18552-L24043	***ABL1***, ex 4	NM_007313.2; 811-812	GCCCAAACCAAA-AATGGCCAAGGC	29.2 kb
319	12516-L29680	***ABL1***, ex 12	NM_007313.2; 2226-2227	TCGAAAAGAGCG-AGGTCCCCCGGA	243.5 kb
361	18553-L23891	***NUP214***, ex 2	NM_005085.4; 206-207	AGAATCTTTGAC-TCCCCTGAGGAA	47.9 kb
492	18547-L24044	***NUP214***, ex 23	NM_005085.4; 3296-3297	TCTGCTAGCAAA-ATTATTCCTCAA	-

***PTEN* gene**, at 10q23.31
PTEN deletions occurring in 9% of T-ALL patients are associated with early treatment failure and may contribute to increased resistance to chemotherapy (Gutierrez et al. 2009; Jotta et al. 2010). *PTEN* mutations in T-ALL seem to cluster in exon 7 (Zuurbier et al. 2012).
Exon numbering for *PTEN* is according to LRG_311.

233	13685-L17760	***PTEN***, ex 1	NM_000314.8; 781-782	CCTGCAGAAGAA-GCCCCGCCACCA	93.5 kb
214 #	13691-L23847	***PTEN***, ex 7	NM_000314.8; 1550-1551	ACACGACGGGAA-GACAAGTTCATG	0.1 kb
439	13692-L23864	***PTEN***, ex 7	NM_000314.8; 4 nt after ex 7	TAAAAAAGGTTT-GTACTTTACTTT	7.6 kb
475 #	13696-L17520	***PTEN***, ex 9	NM_000314.8; 2171-2170 reverse	AGAGAATTGTTC-CTATAACTGGTA	-

***LMO1* gene**, at 11p15.4
LMO1 is a transcriptional regulator, which is involved in translocations between *TRB* (7q34) and *TRA/D* (14q11) leading in overexpression of *LMO1*. *LMO1* has been recognized to be amplified and to act as an oncogene in neuroblastoma (Wang et al. 2011). Co-expression of *LMO1* and *TAL1* was shown to decrease disease latency (Girardi et al. 2017).
Exon numbering for *LMO1* is according to LRG_508.

343 Ж	16717-SP0380-L19731	***LMO1***, ex 4	NM_002315.3; 935-934 and 899-898 reverse	CCTCATAGTCCA-36nt spanning oligo-TGTCTCCCACAC	5.7 kb
244 Ж	16714-SP0381-L23885	***LMO1***, ex 2	NM_002315.3; 634-633 and 598-597 reverse	GTACTTGTCCAA-36nt spanning oligo-ACAGCCCGCACA	26 **M**b to *LMO2* gene

***LMO2* gene**, at 11p13
Deletion of 11p13, including exon 1 of the *LMO2* gene, activates *LMO2* expression in 4% of paediatric T-ALL patients by fusing *RAG2* exon 1 to exon 2 of *LMO2* (Van Vlierberghe et al. 2006).
Exon numbering for *RAG2* is according to LRG_99.
° A decreased signal of the probes for *LMO2* ex 1, *CD44* and *SLC1A2* is indicative for the formation of an *LMO2-RAG2* fusion.

196	12538-L23846	***LMO2***, ex 6	NM_005574.4; 1459-1460	ACATAGCATCCA-AGTGGCATAATT	33.0 kb
382 °	12558-L23858	***LMO2***, ex 1	NM_005574.4; 77 nt before ex 1	AGCACATCTGGT-GTGAGAGAGCTC	1.3 **M**b
426 °	00669-L23838	***CD44***, ex 19	11p13	CAGAAACTCCAG-ACCAGTTTATGA	36.4 kb
481 °	18698-L29605	***SLC1A2***, ex 13	11p13	AGTGCATGAAGA-TATTGAAATGAC	1.3 **M**b
152	18551-L23889	***RAG2***, ex 2	NM_001243786.2; 715-716	GCATAACCATGT-CAAACTGAAGCC	4.1 kb
351	16520-L23853	***RAG2***, ex 1	NM_001243786.2: 97-98	GTTTAGCGGCAA-AGATTCAGAGAG	-

***NF1* and *SUZ12* genes**, at 17q11.2
An *NF1* deletion detected in 11% of T-ALL patients may correlate with poor response to induction therapy (Balgobind et al. 2008; Matteucci et al. 2010). The *SUZ12* gene in the same chromosomal region has also been shown to be inactivated by loss-of-function mutations and deletions in T-ALL patients (Ntziachristos et al. 2012; Zhang et al. 2012).
Exon numbering for *NF1* is according to LRG_214.

250 #	03849-L18072	***NF1***, ex 26	NM_000267.3; 3816-3817	TGAGGCACTGTA-CGGTCCTTGCAA	141.2 kb
400	02530-L23856	***NF1***, ex 58	NM_000267.3; 8748-8749	GCCACTGTAACA-GTGGACGAACTC	614.4 kb
504	18539-L23848	***SUZ12***, ex 10	NM_015355.4; 1407-1408	CATCAGGAAAAC-AAGCCTGGTTCA	8.4 kb
311	18705-L23805	***SUZ12***, ex 15	NM_015355.4; 2084-2085	AGAAGTGATGAA-ACTCTGGAATCT	-

***PTPN2* gene**, at 18p11.21
A *PTPN2* deletion is detected in 6% of all T-ALL patients. *PTPN2* has been identified as a negative regulator of *NUP214-ABL1* and JAK1 kinase activity (Kleppe et al. 2010; Kleppe et al. 2011).

462	15970-L23850	***PTPN2***, ex 9	NM_080422.3; 142 nt after ex 9	TCTGCACTAGTA-ACTGACAGTGCT	36.8 kb
208 Ж	18549-SP0318-L23866	***PTPN2***, ex 4	NM_080422.3; 363-364 and 390-391	TCACAGGGTCCA-27nt spanning oligo-CTTATGGTTTGG	28.2 kb
239 Ж	15955-SP0317-L18107	***PTPN2***, ex 2	NM_080422.3; 219-220 and 255-256	AAGTTTCCAGAA-36nt spanning oligo-TGTAAGTACTTG	25.0 kb
176 Ж ±	15951-SP0316-L23881	***PTPN2***, ex 1	NM_080422.3; 93-94 and 126-127	CTCGCTCCCGCA-33nt spanning oligo-GAGTTGGATACT	-

***PHF6* gene**, at Xq26.2
PHF6 inactivation is detected in 16% and 38% of paediatric and adult T-ALL cases, respectively. Inactivation occurs by deletion in 21% and by point mutation in 79% of inactivation cases, and correlates with poor survival in adult T-ALL (Van Vlierberghe et al. 2010).
Exon numbering for *PHF6* is according to LRG_629 (RefSeq transcript NM_001015877).

190 ¬	06104-L05559	*SH2D1A*	Xq25	TGAGCTCGTTTT-AACTGAAGTGTG	10 Mb
137	18550-L29679	***PHF6***, ex 1	NM_001015877.2; 110-111	TCTTTCTCTTTA-CCCTCATTGGCG	4.6 kb
161	15948-L23843	***PHF6***, ex 3	NM_001015877.2; 377-378	CACACTCTGATA-ATGAAAGTCTTG	35.8 kb
226	15954-L23884	***PHF6***, ex 7	NM_001015877.2; 823-824	AGCCCTAGTGAC-ACCAGGCCTAAA	12.1 kb
391	15965-L24481	***PHF6***, ex 11	NM_001015877.2 1649-1650	TTGTTTAGTGGA-TCCATACTCAAA	2.2 Mb
202 ¬	02902-L02296	*ARHGEF6*	Xq26.3	GATGCTCAAATC-CTTAAAGTGATC	-

[a] See section Exon numbering on page 1 for more information.

[b] Only partial probe sequences are shown. Complete probe sequences are available at www.mrcholland.com. Please notify us of any mistakes: info@mrcholland.com.

± SNV rs200164592 could influence the probe signal. In case of apparent deletions, it is recommended to sequence the region targeted by this probe.

« Probe located in or near a GC-rich region. A low signal can be caused by salt contamination in the DNA sample leading to incomplete DNA denaturation, especially of GC-rich regions.

Ж This probe consists of three parts and has two ligation sites. A low signal of this probe can be due to depurination of the sample DNA, e.g. due to insufficient buffering capacity or a prolonged denaturation time. When this occurs in reference samples, it can look like an increased signal in the test samples.

¬ Flanking probe. Included to help determine the extent of a deletion/duplication. Copy number alterations of only the flanking or reference probes are unlikely to be related to the condition tested.

This probe's specificity relies on a single nucleotide difference compared to a related gene or pseudogene. As a result, an apparent duplication of only this probe can be the result of a non-significant single nucleotide sequence change in the related gene or pseudogene.

SNVs located in the target sequence of a probe can influence probe hybridization and/or probe ligation. Please note: not all known SNVs are mentioned in the tables above. Single probe aberration(s) must be confirmed by another method.

Related SALSA MLPA probemixes

- **P056 TP53 (CE):** Contains probes for each exon of the *TP53* gene.
- **P081/P082 NF1 mix1 / 2 (CE):** Contain probes for each exon of the *NF1* gene.
- **P105 Glioma-2:** Contains probes for *PDGFRA*, *EGFR*, *CDKN2A*, *PTEN*, *CDK4*, *MDM2*, *NFKBIA* and *TP53*.
- **P122 NF1-area**: Contains probes for the *NF1* area on chromosome 17q11.2.
- **P202 IKZF1-ERG:** Contains probes for every exon of the *IKZF1* and *ERG* genes and also includes probes for the *CDKN2A/2B* and 14q32.33 region.
- **P225 PTEN (CE):** Contains probes for each exon of the *PTEN* gene.
- **P327 iAMP21-ERG:** Contains probes for *RUNX1*, *ERG* and for other chromosome 21 genes.
- **P329 CLRF2-CSF2RA-IL3RA:** Contains probes for *CRLF2*, *CSF2RA*, and the *IL3RA* region in the Xp22.33 PAR region.
- **P335 ALL-IKZF1 (CE):** Contains probes for *IKZF1*, *CDKN2A/2B*, *EBF1*, the Xp22 PAR-region, *PAX5*, *ETV6*, *BTG1* and *RB1*.
- **P370 BRAF-IDH1-IDH2:** Contains probes for copy number detection of *BRAF*, *CDNK2A/2B*, *FGFR1*, *MYB* and *MYBL1* genes, several fusion gene products and *BRAF*, *IDH1* and *IDH2* mutations.
- **P377 Hematologic malignancies:** Contains probes for screening of DNA samples for the most common copy number changes associated with ALL, AML, CLL, CML, MDS and lymphomas.
- **P419 CDKN2A/2B-CDK4:** Contains at least one probe for each exon of the *CDKN2A/2B* and *CDK4* genes.
- **ME024 9p21 CDKN2A/2B region:** Contains probes for *CDKN2A/2B* (including several methylation-specific probes), *MTAP*, *MIR31* and *PAX5*.

References

- Balgobind BV et al. (2008). Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for Neurofibromatosis. *Blood*. 111:4322-28.
- Brown L et al. (1990). Site-specific recombination of the TAL-1 gene is a common occurrence in human T cell leukemia. *EMBO J*. 9:3343-51.
- Cave H et al. (2004). Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC Studies 58881 and 58951. *Blood*. 103:442-50.
- Clappier E et al. (2007). The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. *Blood*. 110:1251-61.
- Fizzotti M et al. (1995). Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. *Blood*. 85:2685-90.
- Girardi T et al. (2017). The genetics and molecular biology of T-ALL. *Blood*. 129:1113-23.
- Graux C et al. (2004). Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. *Nat Gen*. 36:1084-9.
- Graux C et al. (2009). Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. *Leukemia*. 23:125-33.
- Gutierrez A et al. (2009). High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. *Blood*. 114:647-50.
- Gutierrez A et al. (2010). Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. *Blood*. 115:2845-51.
- Hömig-Hölzel C and Savola S. (2012). Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. *Diagn Mol Pathol*. 21:189-206.
- Iacobucci I and Mullighan CG. (2017). Genetic basis of acute lymphoblastic leukemia. *J Clin Oncol*. 35:975-83.
- Jotta P et al. (2010). Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. *Leukemia*. 24:239-42.
- Kleppe M et al. (2010). Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. *Nat Gen*. 42:530-5.
- Kleppe M et al. (2011). PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. *Blood*. 117:7090-8.
- Lahortiga I et al. (2007). Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. *Nat Genet*. 39:593-5.
- Matteucci C et al. (2010). Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. *Br J Heamatol*. 149:70-8.
- Mullighan CG et al (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature*. 446:758-64.
- Ntziachristos P et al. (2012). Genetic inactivation of the Polycomb Repressive Complex 2 in T cell acute lymphoblastic leukemia. *Nat Med*. 18:296-301.
- O'Neil J et al. (2007). Alu elements mediate MYB gene tandem duplication in human T-ALL. *J Exp Med*. 204:3059-66.
- Remke M et al. (2009). High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. *Blood*. 114:1053-62.
- Schouten JP et al. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res.* 30:e57.
- Schwartz M et al. (2007). Deletion of exon 16 of the dystrophin gene is not associated with disease. *Hum Mutat.* 28:205.
- Simon C et al. (2012). A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. *Genes Dev*. 26:651-6.

- Sulong S et al. (2009). A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. *Blood*. 113:100-7.
- Usvasalo A et al. (2008). CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. *Leukemia Res*. 32:1228-35.
- Van Vlierberghe P et al. (2006). The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. *Blood*. 108:3520-9.
- Van Vlierberghe P et al. (2010). PHF6 mutations in T-cell acute lymphoblastic leukemia. *Nat Gen*. 42:338-42.
- Varga RE et al. (2012). MLPA-based evidence for sequence gain: pitfalls in confirmation and necessity for exclusion of false positives. *Anal Biochem*. 421:799-801.
- Wang K et al. (2011). Integrative genomics identifies LMO1 as a Neuroblastoma oncogene. *Nature*. 469:216-20.
- Yamada Y et al. (1997). Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. *J Clin Oncol*. 15:1778-85.
- Zhang J et al. (2012). The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*. 481:157-63.
- Zuurbier L et al. (2012). The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. *Haematologica*. 97:1405-13.

Selected publications using SALSA MLPA Probemix P383 T-ALL

- Bhatia P et al. (2020). PEST domain NOTCH mutations confer a poor relapse free survival in pediatric T-ALL: Data from a tertiary care centre in India. *Blood Cells Mol Dis*. 82:102419.
- Benard-Slagter A et al. (2017). Digital Multiplex Ligation-Dependent Probe Amplification for detection of key copy number alterations in T- and B-Cell lymphoblastic leukemia. *J Mol Diagn*. 19:659-72.
  Fuhrmann S et al. (2018). Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. *Br J Haematol*. 183:96-103.
- Jang W et al. (2019). CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia. *Exp Mol Med*. 51:4.
- Kunz JB et al. (2015). Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. *Haematologica*. 100:1442-50.
- Noronha EP et al. (2019). The profile of immunophenotype and genotype aberrations in subsets of pediatric T-cell acute lymphoblastic leukemia. *Front Oncol*. 9:316.
- Richter-Pechanska P et al. (2017). Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. *Blood Cancer J*. 7:e523.
- Tesio M et al. (2017). Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. *Leukemia*. 31:2594-600.
- Thakral D et al. (2019). Rapid identification of key copy number alterations in B- and T-cell acute lymphoblastic leukemia by digital multiplex ligation-dependent probe amplification. *Front Oncol*. 9:871.
- Vega-Garcia N et al. (2021). Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. *Front Pediatr*. 8:614521.
- Yeh TC et al. (2019). Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. *Pediatr Blood Cancer*. 66:e27496.

P383 product history	
Version	*Modification*
A2	Changes in length of several probes but no change in the sequences detected.
A1	First release.

Implemented changes in the product description
Version A2-04 – 17 January 2023 (04P) - Exon numbering of the *CDKN2A* gene has been changed according to MANE in Table 1 and 2. See also explanation on page 2. - Ligation site of the CDKN2A probe 18753-L24594 has been updated.
Version A2-03 – 15 March 2021 (04P) - Typo corrected in the title of the Table 2. - P383 specific note added on page 4. - New selected publication for P383 added on page 12. - Order of the selected publications changed to alphabetical. - Other minor typos corrected.
Version A2-02 – 19 January 2021 (04P) - Positive sample table on page 3 adjusted: information changed for one sample and three positive samples removed upon critical review of the MLPA data with Coffalyser.Net software.
Version A2-01 – 05 January 2021 (04P) - Product description rewritten and adapted to a new template. - Ligation sites of the probes targeting the LEF1, CASP8AP2, MYB, EZH2, MLLT3, CDKN2A, NUP214, PTEN, LMO1, LMO2, RAG2, SUZ12, PTPN2 and PHF6 genes updated according to new version of the NM_ reference sequence. - Warning added to Table 2 for probe specificity relying on a single nucleotide difference between target gene and related gene or pseudogene. - Warning added to Tables 1 and 2 for SNV rs200164592 in PTPN2 probe at 176 nt. - Small changes of probe lengths in Table 1 and 2 in order to better reflect the true lengths of the amplification products. - Reference probe function removed from MTTL3 and MTAP probes.
Version 08 – 15 March 2019 (T08) - Information about related MLPA probemixes updated. - New references added on page 2. - Exon numbering for EZH2 has been updated according to the latest LRG information (LRG_531).
Version 07 – 03 March 2017 (T08) - Several warnings on sensitivity to incomplete DNA denaturation updated in Tables 1 and 2. Warning added for LMO2 probe 12538-L23846 (196 nt); warnings removed for PTPN2 probe 18549-SP0318-L23866 (208 nt); NF1 probe 03849-L18072 (250 nt); and LMO1 probe 16717-SP0380-L19731 (343 nt).
Version 06 – 27 February 2017 (T08) - Product description adapted to the updated product version (version number changed, Tables 1 and 2 modified). - New references added on page 2. - Exon and/or NM sequence information updated in Tables 1 and 2 for the TAL1, MLLT3, CDKN2A, NUP214 PTEN, SUZ12 and PTPN2 genes. - Various minor textual changes throughout the document.
Version 05 – 17 January 2017 (T08) - Warning added in Table 1, 400 nt probe 02530-L23856. - Various minor textual changes.

More information: www.mrcholland.com; www.mrcholland.eu	
	MRC Holland bv; Willem Schoutenstraat 1 1057 DL, Amsterdam, The Netherlands
E-mail	info@mrcholland.com (information & technical questions) order@mrcholland.com (orders)
Phone	+31 888 657 200